GlassScriptPhysician profile
Jason M Wilder
NPI 1952327629
$11,847.39
in general payments reported to CMS, 2019-2025
35 companies · $2,020 in 2025
The $2,020 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $1,159 · 2021: $1,124 · 2022: $1,696 · 2023: $2,398 · 2024: $2,237 · 2025: $2,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,561 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,560.56 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,318.70 | 2019-2025 | Cabtreo, Jublia, Duobrii |
| Pfizer INC. | $1,264.67 | 2019-2025 | |
| Janssen Biotech, INC. | $1,055.03 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Galderma Laboratories, L.P. | $1,011.84 | 2020-2025 | Aklief |
| Incyte Corporation | $971.65 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $753.17 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $596.43 | 2019-2025 | Odomzo, Blu-U, Ilumya |
| Almirall LLC | $586.68 | 2019-2025 | Seysara, Klisyri |
| Journey Medical Corporation | $486.11 | 2020-2025 | |
| Abbvie INC. | $402.76 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $382.00 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $358.32 | 2019-2025 | |
| Leo Pharma INC. | $290.58 | 2019-2025 | Adbry, Anzupgo |
| Organon LLC | $283.86 | 2025 | Vtama, Nexplanon |
| Novartis Pharmaceuticals Corporation | $281.53 | 2021-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $256.51 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $201.27 | 2020-2024 | Dupixent |
| Vyne Pharmaceuticals INC. | $184.62 | 2020-2021 | |
| Genzyme Corporation | $165.67 | 2020-2025 | |
| Prugen, INC. Pharmaceuticals | $157.10 | 2020 | |
| Dermira, INC. | $155.78 | 2019-2020 | |
| Lilly USA, LLC | $154.46 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $115.10 | 2022-2025 | Bimzelx |
| Amgen INC. | $99.15 | 2021-2024 | Otezla, Enbrel |
| Botanix Sb INC | $74.59 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $47.14 | 2024-2025 | Ycanth |
| Sandoz INC. | $38.54 | 2020 | |
| Nobelpharma America, LLC | $36.24 | 2025 | |
| Genentech USA, INC. | $25.95 | 2024 | Xolair |
| Mylan Pharmaceuticals INC. | $21.79 | 2019 | |
| Aclaris Therapeutics, INC. | $18.49 | 2019 | |
| Mission Pharmacal Company | $14.47 | 2020 | |
| Allergan, INC. | $13.29 | 2019 | |
| Nabriva Therapeutics, Plc | $12.38 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Wilder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.